Blueprint Medicines (BPMC) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Forty Seven (NASDAQ:FTSV) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.

Which has more volatility and risk, BPMC or FTSV?

Blueprint Medicines has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Forty Seven has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.

Does the MarketBeat Community prefer BPMC or FTSV?

Blueprint Medicines received 392 more outperform votes than Forty Seven when rated by MarketBeat users. However, 68.12% of users gave Forty Seven an outperform vote while only 67.98% of users gave Blueprint Medicines an outperform vote.

Company	Underperform	Outperform
Blueprint Medicines	Outperform Votes 533 67.98%	Underperform Votes 251 32.02%
Forty Seven	Outperform Votes 141 68.12%	Underperform Votes 66 31.88%

Is BPMC or FTSV more profitable?

Forty Seven has a net margin of 0.00% compared to Blueprint Medicines' net margin of -29.48%. Forty Seven's return on equity of -50.38% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-29.48%	-112.30%	-26.87%
Forty Seven	N/A	-50.38%	-44.35%

Which has stronger earnings & valuation, BPMC or FTSV?

Forty Seven has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Forty Seven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$249.38M	22.59	-$506.98M	-$2.11	-42.03
Forty Seven	$15.68M	293.33	-$87.62M	-$2.34	-40.82

Does the media prefer BPMC or FTSV?

In the previous week, Blueprint Medicines had 20 more articles in the media than Forty Seven. MarketBeat recorded 20 mentions for Blueprint Medicines and 0 mentions for Forty Seven. Blueprint Medicines' average media sentiment score of 0.57 beat Forty Seven's score of 0.00 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company	Overall Sentiment
Blueprint Medicines	Positive
Forty Seven	Neutral

Do institutionals & insiders believe in BPMC or FTSV?

71.8% of Forty Seven shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Comparatively, 37.4% of Forty Seven shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts rate BPMC or FTSV?

Blueprint Medicines presently has a consensus target price of $122.11, suggesting a potential upside of 37.68%. Given Blueprint Medicines' stronger consensus rating and higher probable upside, equities research analysts clearly believe Blueprint Medicines is more favorable than Forty Seven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.71
Forty Seven	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Blueprint Medicines beats Forty Seven on 11 of the 19 factors compared between the two stocks.